Register  Login

                            


A Review on Rheumatoid Arthritis and its Aspiratory Affiliations

Author(s): AKANKSHA AGGARWAL*, KRITIKA SHARMA, RIYA NAGPAL AND SACHIN

When rheumatoid arthritis (RA) is associated with Interstitial lung disease (ILD), it contributes largely to morbidity and mortality in the population, which accounts roughly for 20% of all deaths. It is estimated that approximately half of RA patients would experience respiratory problems at some point in their lives1. Diagnosis can be difficult since individuals with severe arthritic symptoms are unlikely to state dyspnea due to a general decline in physical activity. Rheumatic disorders raise the risk of uncontrolled growth, either as a result of the disease itself or as a result of the drugs used to treat the rheumatic diseases and their toxicity. Methotrexate monotherapy is suggested as first-line treatment, with short-term glucocorticoid therapy added if the risk/benefit ratio suggests it. Patients who do not respond to this method (no response after 3 months or target not met after 6 months) may be evaluated for additional synthetic DMARD treatment or methotrexate with a biologic, depending on predicted variables and patient characteristics. In addition to the disease's complications, immunosuppressive drugs and other medicines used to treat RA can be pneumotoxic and could hinder wound repair or healing. In this review article, we will deliberate the entire pathophysiology, pathogenesis, and various manifestations due to arthritis along with an efficient clinical set of rules for the diagnosis of RA-ILD. This study shall help to investigate the known and experimental treatment options that may have some aid in the management of RA-ILD